LepVax as a Promising Specific Vaccine for Leprosy: A Narrative Review
Leprosy is a disease with a high rate of transmission around the world. Leprosy is hard to eradicate because treatment is difficult and there is no vaccine to prevent it. The response of the immune system plays a role in determining the form of the clinical manifestation of leprosy. LepVax is a vaccine made from the Mycobacterium leprae antigens ML2531, ML2380, ML2055 and ML2028 formulated with the Toll-like receptor 4 agonist Glucopyranosyl Lipid Adjuvant in Stable Emulsion. LepVax can prevent infection with M. leprae through stimulation of the immune system and resulting regulation of pathogenic bacteria. LepVax can prevent nerve cell damage which is a target of the M. leprae bacterium. Further research is needed on the safety of LepVax as a vaccine to eradicate leprosy in the future.